Adendra Therapeutics is a technology company.
Adendra Therapeutics is a technology company.
Adendra Therapeutics has raised $53.0M across 1 funding round.
Adendra Therapeutics has raised $53.0M in total across 1 funding round.
Adendra Therapeutics has raised $53.0M in total across 1 funding round.
Adendra Therapeutics's investors include Joseph A. Yanchik III, Michael Ehlers, ATP (Apple Tree Partners).
Adendra Therapeutics is a biotechnology company developing novel immunotherapies that modulate dendritic and other immune cells to treat solid tumors and autoimmune diseases.[1][2][6] It builds small molecule and biologic medicines based on insights into dendritic cell biology, targeting immunological control of cancer and T cell-driven autoimmunity, primarily serving patients with hard-to-treat cancers and autoimmune conditions.[2][3][6] The company solves unmet needs in oncology and immunology by augmenting immune responses where current therapies fall short, with early momentum from its 2021 spin-out status and backing by accelerator ATP, positioning it for preclinical advancement.[2]
Adendra Therapeutics emerged in 2021 as a spin-out from The Francis Crick Institute's Immunobiology Laboratory, led by Professor Caetano Reis e Sousa, in collaboration with Raj Mehta, Ph.D., an Entrepreneur-in-Residence at ATP (Atlas Venture's therapeutics accelerator).[2] Mehta, who previously founded GammaDelta Therapeutics (acquired by Takeda) and Revitope Oncology, co-founded Adendra and serves as CEO, bringing expertise in immunotherapy development.[2] ATP launched the company to translate Reis e Sousa's pioneering dendritic cell research into therapeutics, marking ATP's first UK-based venture; it was formally incorporated on August 10, 2021, as a private limited company focused on biotechnology R&D (SIC 72110).[2][4] Early traction stemmed from this academic-industry partnership, enabling rapid setup in Potters Bar, UK.[2][4]
Adendra stands out in immunotherapy through:
Adendra rides the wave of next-generation immunotherapies, shifting from broad checkpoint inhibitors to cell-specific modulation amid rising solid tumor resistance and autoimmune prevalence.[1][2][6] Timing aligns with post-2020 advances in dendritic cell biology, fueled by AI-driven discovery and mRNA vaccine lessons, positioning it favorably in a $100B+ oncology/immunology market growing 8-10% annually.[2] Market forces like regulatory emphasis on precision immunology (e.g., FDA/EMA fast-tracks) and investor interest in UK biotechs bolster it; Adendra influences the ecosystem by validating academic spin-outs and ATP's transatlantic model, potentially spawning follow-on ventures in Europe.[2][4]
Adendra is primed for Series A funding and IND-enabling studies by 2026-2027, with lead candidates targeting high-need solid tumors like melanoma or lung cancer and autoimmune indications like rheumatoid arthritis.[2][4] Trends in multimodal immunotherapies and combination regimens will shape its path, amplifying dendritic modulation's role in overcoming resistance. Its influence may evolve from early-stage innovator to pipeline leader, especially if ATP's network secures partnerships with big pharma, echoing GammaDelta's Takeda success—ultimately redefining immunogenicity tuning for intractable diseases.[2] This positions Adendra as a high-upside bet in precision biotech.
Adendra Therapeutics has raised $53.0M across 1 funding round. Most recently, it raised $53.0M Series A in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $53.0M Series A | Joseph A. Yanchik III, Michael Ehlers, ATP (Apple Tree Partners) |